Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* Stable fiber therapy~* Normal colonoscopy/sigmoidoscopy~* Able to refrain from use of medications known to treat or associated with constipation symptoms~* Experiences abdominal discomfort/pain associated with bowel movements~* Reports decreased bowel movement frequency and/or other symptoms associated with constipation~Exclusion Criteria:~* Diarrhea-predominant or alternating (diarrhea \& constipation cycling) IBS, or constipation other than that associated with IBS~* Open gastrointestinal or abdominal surgery prior to IBS onset~* Organic bowel disorder, mechanical bowel obstruction, pseudo-obstruction, unexplained weight loss or rectal bleeding~* Uncontrolled cardiovascular, liver or lung disease, neurologic or psychiatric disorder, other systemic disease, or abnormal laboratory tests per investigator discretion~* If female, is currently pregnant or nursing, or plans to become pregnant or nurse during the clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).